https://www.selleckchem.com/pr....oducts/s64315-mik665
Background People with type 1 diabetes who use continuous subcutaneous insulin infusion (CSII, or insulin pump therapy) often remove their pump before extended periods of exercise, but this approach might result in reduced glycaemic control and increased risk of hyperglycaemia and ketogenesis. We aimed to assess the efficacy and safety of a hybrid approach, in which basal insulin delivery was divided between CSII and a daily injection of insulin degludec. Methods In this single-centre, open-label, proof-of-concept, randomised cros
Like
Comment
Share
